M

Michele Ceribelli

National Institutes of Health

ORCID: 0000-0001-9857-9521

Publishes on Ubiquitin and proteasome pathways, Computational Drug Discovery Methods, PARP inhibition in cancer therapy. 347 papers and 5.7k citations.

347Publications
5.7kTotal Citations
Ubiquitin and proteasome pathwaysComputational Drug Discovery MethodsPARP inhibition in cancer therapyLymphoma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin, Kelli M. Wilson, Michele Ceribelli et al.|Science Translational Medicine|2019
Cited by 256Open Access

) production via nicotinamide phosphoribosyltransferase (NAMPT) inhibition demonstrated that metabolic catastrophe drives the combination-induced cytotoxicity. This study provides a comprehensive single-agent and combinatorial drug screen for DMG and identifies concomitant HDAC and proteasome inhibition as a promising therapeutic strategy that underscores underrecognized metabolic vulnerabilities in DMG.